Presentations on ROS1+ Cancer at IASLC #WCLC2018

Members of The ROS1ders will be attending The International Association for the Study of Lung Cancer’s (IASLC) annual World Conference on Lung Cancer (WCLC) in Toronto, Canada, September 23-26, 2018.  The Twitter hashtag for the conference is #WCLC2018.

Presentations that will mention ROS1+ cancer are listed below.  The abstract book containing these and other WCLC presentations is available online.
Download PDF of the Abstract Book: Click Here.

The complete scientific program for #WCLC2018 is available here.

DAY/TIME SESSION PRESENTATION  AUTHORS
24-Sep

10:30 –
12:00

MA02 – Improving Outcomes for Patients with Lung Cancer

(Mini Oral Abstract)

MA02.01 – ROS1 Gene Rearrangements Are Associated with an Exaggerated Risk of Peri-Diagnosis Thromboembolic Events Terry L. Ng, Derek E Smith, Rao Mushtaq, Tejas Patil, Anastasios Dimou, Shuo Yang, Qian Liu, Xuefei Li, Caicun Zhou, Flora Yan, I. Alex Bowman, Stephen V Liu, Robert C. Doebele, Dara L. Aisner, Shengxiang Ren, Ross Camidge
MA02.11 – Achieving Value in Cancer Diagnostics: Blood Versus Tissue Molecular Profiling – A Prospective Canadian Study (VALUE) Doreen Anuli Ezeife, Jason S Agulnik, Rosalyn Juergens, Janessa Laskin, Scott A. Laurie, Lisa Le, Desiree Hao, Gwyn Bebb, Jennifer H Law, Stan Skrzypczak, Daniela Juri, Richard B Lanman, Natasha B Leighl
24-Sep

10:30 –
12:00

OA02 – Novel Therapies in ROS1, HER2 and EGFR
(Oral Abstract Session)
 
OA02.01 – Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small Cell Lung Cancer (NSCLC)

 

Robert C. Doebele, Myung-Ju Ahn, Salvatore Siena, Alexander Drilon, Matthew G Krebs, Chia-Chi Lin, Filippo G. De Braud, Thomas John, Daniel S.W. Tan, Takashi Seto, Rafal Dziadziuszko, Hendrick-Tobias Arkenau, Fabrice Barlesi, Christian Rolfo, Jürgen Wolf, Edna Chow-Maneval, Pratik S. Multani, Na Cui, Todd Riehl, Byoung Chul Cho
OA02.02 – Safety and Preliminary Clinical Activity of Ropotrectinib (TPX-0005), a ROS1/TRK/ALK Inhibitor, in Advanced ROS1 Fusion-Positive NSCLC Jessica Jiyeong Lin, Dong-Wan Kim, Alexander Drilon, Robert C. Doebele, Jeeyun Lee, Viola Zhu, Myung-Ju Ahn, John Lim, Shanna Stopatschinskaja, J. Jean Cui, David M Hyman, Ross Camidge, Sai-Hong Ignatius Ou, Alice T. Shaw, Byoung Chul Cho
OA02.03 – Clinical Activity of Lorlatinib in Patients with ROS1+ Advanced Non-Small Cell Lung Cancer: Phase 2 Study Cohort EXP-6 Sai-Hong Ignatius Ou , Alice T. Shaw, Gregory J Riely, Rita Chiari, Jessica R. Bauman, Jill S. Clancy, Holger Thurm, Gerson Peltz, Antonello Abbattista, Ben J Solomon
24- Sep

13:30 – 15:00 

MA04 – Novel Approaches with IO

(Mini Oral Abstract)

MA04.03 – Immunotherapy for Non-Small Cell Lung Cancers (NSCLC) with Oncogenic Driver Mutations: New Results from the Global IMMUNOTARGET Registry Oliver Gautschi, Alexander Drilon, Julie Milia, Amelie Lusque, Laurent Mhanna, Bob T. Li, Joshua K Sabari, Alexis B Cortot, Benjamin Besse, Laura Mezquita, Ben J Solomon, Alesha A Thai, Sebastien Couraud, Remi Veillon, Céline Mascaux, Fabrice Barlesi, Michael Van Den Heuvel, Robert D Schouten, Heather A Wakelee, Angela Mah, D. Ross Camidge, Terry L. Ng, Nir Peled, Yosef Lilach, Sanjay Popat, Sai-Hong Ignatius Ou, Viola Zhu, Vamsidhar Velcheti, Alessandra Curioni Fontecedro, Dilara Akhoundova, Martin Früh, Gerard Zalcman, Valerie Gounant, Silvia Novello, Paolo Bironzo, Enriqueta Felip, Alex Martinez-Marti, Denis Moro-Sibilot, Rafael Rosell, Niki Karachaliou, Martin Schuler, Martin Wiesweg, Joachim Diebold, Julien Mazieres
24-Sep

16:45 – 18:00

P1.01 – Advanced NSCLC

(poster viewing)

P1.01-01 – ROS1-Positive Non-Small Cell Lung Cancer: Real-World Data in Korea Beung Chul Ahn, Sehhoon Park, Sung Won Lim, Hye Ryun Kim, Min Hee Hong, Byoung Chul Cho, Myung-Ju Ahn
P1.01-15 – ROS1-Rearranged Non-Small Cell Lung Cancer Is Associated with High Rate of Venous Thromboembolism: Analysis of The METROS Trial Biagio Ricciuti, Rita Chiari, Lorenza Landi, Anna Maira Morelli, Angelo Delmonte, Gianluca Spitalieri, Diego Cortinovis, Francesco Facchinetti, Sara Pilotto, Claudio Verusio, Antonio Chella, Laura Bonanno, Domenico Galetta, Federico Cappuzzo
P1.01-59 – A Better Real World Practice for ROS1 Positive NSCLC Patients, Driven by the Targeted Next Generation Sequencing(NGS) and the Targeted TKI Yongchang Zhang , Zeng Liang, Nong Yang, yizhi Li
P1.01-67 – Clinical Relevance of ALK/ROS1 Resistance Mutations and Other Acquired Mutations Detected by Liquid Biopsy in Advanced NSCLC Patients Laura Mezquita, Aurélie Swalduz, Cecile Jovelet, Sandra Ortiz-Cuaran, David Planchard, Virginie Avrillon, Gonzalo Recondo, Solène Marteau, Vincent Plagnol, Karen Howarth, Clive Morris, Emma Green, Ludovic Lacroix, Luc Odier, Etienne Rouleau, Pierre Fournel, Caroline Caramella, Claire Tissot, Julien Adam, Maurice Pérol, Luc Friboulet, Pierre Saintigny, Benjamin Besse
P1.01-78 – The Incidence of Brain Metastases in ROS1-Rearranged Non-Small Cell Lung Cancer at Diagnosis and Following Progression on Crizotinib Tejas Patil, Derek E Smith, Paul A. Bunn, Jr., Dara L. Aisner, Anh T Le, Mark Hancock, William T Purcell, Daniel W Bowles, Ross Camidge, Robert C. Doebele
P1.01-95 – Crizotinib Treatment in 29 Advanced NSCLC Chinese Patients with ROS1 Rearrangement——A Single Chinese Cancer Institute Experience Jialei Wang, Chang Liu, Jianhua Chang, Weixin Zhao, Hui Yu, Zhengfei Zhu, Si Sun, Min Fan
P1.01-113 – Analysis of Clinicopathological Features and Clinical Efficacy of Crizotinib in ROS1 Positive Non-Small Cell Lung Cancer Youcai Zhu, Xiaofeng Li, Lixin Wu, Huafei Chen, Wenxian Wang, Chunwei Xu, Meiyu Fang, Jianfa Shen, Kaiqi Du, Wu Zhuang, Yanping Chen, Gang Chen
24-Sep

16:45 – 18:00

P1.03 – Biology

(Poster viewing)

 

P1.03-09 – ROS1 Rearrangement in Pulmonary Sarcomatoid Carcinoma: A Retrospective Study of the Real World Chunwei Xu, Wenxian Wang, Youcai Zhu, Meiyu Fang, Wu Zhuang, Quxia Zhang, Yanping Chen, Ziying Gong, Gang Chen, Tang Feng Lv, Yong Song
24-Sep

16:45 – 18:00

P1.09 – Pathology

 

P1.09-09 – Evaluation of a Novel ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in NSCLC Patients

 

Esther Conde, Susana Hernandez, Rebeca Martinez, Javier De Castro, Ana Collazo-Lorduy, Beatriz Jimenez, Alfonso Muriel, Jose Luis Mate, Teresa Morán, Ignacio Aranda, Bartomeu Massuti, Federico Rojo, Manuel Domine, Irene Sansano, Felip Garcia, Enriqueta Felip, Nuria Mancheño, Oscar Juan, Julian Sanz, Jose Luis Gonzalez-Larriba, Lidia Atienza-Cuevas, Esperanza Arriola-Arellano, Ihab Abdulkader, Jorge Garcia, Carmen Camacho, Delvys Rodríguez-Abreu, Cristina Teixido, Noemi Reguart, Ana Gonzalez-Piñeiro, Martin Lazaro-Quintela, Maria Dolores Lozano, Alfonso Gurpide, Javier Gomez-Roman, Marta Lopez-Brea, Lara Pijuan, Marta Salido, Edurne Arriola, Amparo Company, Amelia Insa, Isabel Esteban, Monica Saiz, Eider Azkona, Ramiro Alvarez, Angel Artal, Ana Belen Enguita, Amparo Benito, Luis Paz-Ares, Pilar Garrido, Fernando Lopez-Rios
P1.09-12 – Simultaneous Platform of Genotyping EGFR, ALK, and ROS1 in Patients with NSCLC Highlights Correlation of ROS1 and PD-L1 Expression Tae-Jung Kim, Jongmin Lee, Jung Im Na
25-Sep

10:30 – 12:00

OA10 – Right Patient, Right Target & Right Drug – Novel Treatments and Research Partnerships

(Oral Abstract Session)

OA10.02 – Oncogene-Driven Patient Groups: A New Era For Research Partnerships Janet Freeman-Daily, Ivy Elkins, Laura Greco, Marcia K Horn, Bonnie Addario, David LeDuc, Robert C. Doebele, Christine Lovly
25-Sep

10:30 – 12:00

MA11 – Biomarkers of IO Response

(Mini Oral Abstract)

MA11.09 – Single-Cell Characterization of the Immunologic Microenvironment in Advanced-Stage, Oncogene-Driven NSCLC Julia Rotow, Caroline McCoach, Ashley Maynard, David Naeger, Yaron Gesthalter, K Pallav Kolli, Spyros Darmanis, Trever G Bivona, Collin Blakely, Jonathan Weissman
25-Sep

1330 – 1500

MA16 – Novel Mechanisms for Molecular Profiling (Mini Oral Abstract)

 

MA16.08 – Clinical Utility of Detecting ROS1 Genetic Alterations in Plasma Ibiayi Dagogo-Jack, Rebecca J Nagy, Lorin A Ferris, Jessica Jiyeong Lin, Justin F Gainor, Richard B Lanman, Alice T. Shaw
MA16.09 – Feasibility, Clinical Relevance of ALK/ROS1 Fusion Variant Detection by Liquid Biopsy in Advanced Non-Small Cell Lung Cancer Aurélie Swalduz, Laura Mezquita, Sandra Ortiz-Cuaran, Cecile Jovelet, Virginie Avrillon, David Planchard, Solène Marteau, Gonzalo Recondo, Séverine Martinez, Karen Howarth, Vincent Plagnol, Clive Morris, Emma Green, Luc Odier, Ludovic Lacroix, Stéphane Hominal, Etienne Rouleau, Claire Tissot, Caroline Caramella, Pierre Fournel, Luc Friboulet, Maurice Pérol, Benjamin Besse, Pierre Saintigny
25-Sep

15:15 – 16:45

MA19 – Genomic Markers of IO Response
(Mini Oral Abstract)
MA19.01 – Efficacy and Genomic Correlates of Response to Anti-PD1/PD-L1 Blockade in Non-Small Cell Lung Cancers Harboring Targetable Oncogenes Natalie Vokes, Elizabeth Jimenez Alguilar, Anika Adeni, Renato Umeton, Lynette M Sholl, Hira Rizvi, Matthew D. Hellmann, Mark M. Awad, Eliezer M. Van Allen
25-Sep

15:15 – 16:45

OA12 – Novel Therapies in MET, RET and BRAF

(Oral Abstract)

OA12.03 – Activity of Crizotinib in MET or ROS1 Positive (+) NSCLC: Results of the AcSé Trial Denis Moro-Sibilot, Nathalie Cozic, Maurice Pérol, Josiane Otto, Julien Mazieres, Pierre-Jean Souquet, Rastislav Bahleda, Marie Wislez, Sophie De Guibert, Bertrand Mennecier, Christos Chouaid, Renaud Sabatier, Suzanna Bota, Radj Gervais, Véronique Verriele, Véronique Haddad, Gilbert Ferretti, Frédérique Nowak, Céline Mahier – Ait Oukhatar, Gilles Vassal
25-Sep

16:45 – 18:00

P2.01 – Advanced NSCLC

(Poster viewing)

 

P2.01-50 – Thromboembolism in ROS1 Rearranged Non-Small Cell Lung Cancer Nick Pavlakis, Malinda Itchins, Marliese Alexander, Thomas John, Steven Chuan-Hao Kao, Brett G.M Hughes, Sarah A Hayes, Viive M Howell, Rozelle Harvie, Stephen J Clarke, Michael Millward, Adrian Lee
25-Sep

16:45 – 18:00

P2.09 – Pathology

(Poster viewing)

 

P2.09-13 – Correlation of ROS1 (SP384) Immunohistochemistry with ROS1 Rearrangement Determined by Fluorescence in Situ Hybridization Catherine H Le, Richard S.P. Huang, Derek Smith, Bill Richardson, Wen-Wei Liu, Amy Elizabeth Hanlon Newell, Greg Pate, Ina Menzl
26-Sep

12:00 – 13:00

P3.13 – Targeted Therapy

(Poster viewing)

P3.13-04 – Lorlatinib in Anaplastic Lymphoma Kinase and Proto-Oncogene Tyrosine-Protein Kinase ROS-Positive Non-Small Cell Lung Cancer Marthe Sentijna Paats, Jorien Minnema-Luiting, Robin Cornelissen, Joachim G.J.V. Aerts
26-Sep

12:00 – 13:00

P3.CR – Case Reports

(Poster viewing)

P3.CR-04 – Lung Cancer with Concurrent ROS1 Rearrangement and KRAS Mutation: A Case Report Youcai Zhu, Chunwei Xu, Wenxian Wang, Kaiqi Du, Wu Zhuang, Meiyu Fang
P3.CR-13 – Dual Drive Coexistence of EML4-ALK Fusion and TPM3-ROS1 Fusion Lung Adenocarcinoma: A Case Report Youcai Zhu, Chunwei Xu, Wenxian Wang, Wu Zhuang, Gang Chen, Kaiqi Du
P3.CR-11 – ROS1 Fusion and MET Amplification Dual Drive Coexistence in Lung Adenocarcinoma and Response to Crizotinib: A Case Report Chunwei Xu, Wenxian Wang, Zhengbo Song, Quxia Zhang, Wu Zhuang, Yanping Chen, Gang Chen, Meiyu Fang, Tang Feng Lv, Yong Song
26-Sep

13:30 – 15:00

MA26 – New Therapies and Emerging Data in ALK, EGFR and ROS1
(Mini Oral Abstract)
 
MA26.07 – ROS1 (SP384) Immunohistochemistry Inter-Reader Precision Between 12 Pathologists
 
Keith M Kerr, Amy Elizabeth Hanlon Newell, Wen-Wei Liu, Lukas Bubendorf, Reinhard Büttner, Mark Kockx, Myriam Kossai, Fernando Lopez-Rios, Antonio Marchetti, Ivonne Marondel, Andrew G Nicholson, Buge Aysim Oz, Patrick Pauwels, Frederique Penault-Llorca, Giulio Rossi, Vanessa Rüsseler, Erik Thunnissen, Greg Pate, Bryce Portier, Claire Faure, Catherine H Le, Derek Smith, Ina Menzl, Richard S.P. Huang

Published by

Gray Connections

I was diagnosed with non-small cell lung cancer in May 2011. The cancer became metastatic in October 2011. No, I never smoked anything (except a salmon). I've had no evidence of disease since January 2013 thanks to precision medicine, clinical trials, and other patients. ANYONE can get lung cancer. Using my engineering degrees (MIT SBME 1978, Caltech Aeronautics MS 1984 and ENGR 1986), I enjoyed a 20-year career in aerospace systems engineering as a technical translator of sorts: I researched a scientific or engineering subject and helped others understand how this new gizmo could benefit them. In the time I have left, I want to use my skills to help others who have lung cancer, and increase the visibility and knowledge of lung cancer among those who don't. I also study brain research, enjoy traveling, write science fiction, and geek out about all sorts of science stuff.